Swissport Drives Pharma Cold Chain Growth at EuroAirport Basel

Why It Matters

The milestone signals accelerating demand for airport‑based cold‑chain logistics, strengthening Basel’s position as a key European pharma hub and giving Swissport a competitive edge in a fast‑growing market.

Key Takeaways

• 1,000 temperature-controlled containers processed at Basel since Feb 2025.
• Monthly pharma cargo now 200‑250 RKN units, showing rapid growth.
• Handling time cut by ~70%, lowering CO₂ emissions.
• New reusable thermal covers keep temps stable for three hours.
• Swissport operates 24 certified pharma centers and 65 warehouses globally.

Pulse Analysis

The rise of biologics and temperature‑sensitive medicines has turned air cargo into a critical link for global pharmaceutical distribution. EuroAirport Basel‑Mulhouse‑Freiburg, already a logistics crossroads for Europe, has become a focal point for this shift thanks to Swissport’s “cool+connect” platform, launched in February 2025. Within a year the facility has processed more than 1,000 temperature‑controlled containers, pushing monthly throughput to 200‑250 RKN‑equivalent units. This volume surge underscores Basel’s growing reputation as a gateway for life‑science exports to Asia, the United States, and other key markets.

Swissport’s integrated digital monitoring and on‑site consolidation dramatically streamline the cold‑chain workflow. By loading shipments directly into Active Cooltainers at the airport, the company eliminates off‑site trucking loops, slashing handling time by roughly 70 percent and cutting CO₂ emissions. The end‑to‑end temperature control—from receipt through airside transport—maintains the +2 °C to +8 °C band required for most vaccines and biologics, reducing the risk of temperature excursions that can compromise product efficacy and trigger costly recalls.

The recent introduction of reusable thermal covers for cargo dollies adds another layer of resilience, keeping cargo within the required temperature range for up to three hours during intra‑airport transfers, even under extreme weather. Coupled with Swissport’s global network of 24 certified pharma centers and 65 pharma‑capable warehouses, the Basel hub positions the company to capture further market share as manufacturers seek streamlined, sustainable logistics solutions. Analysts expect the European cold‑chain market to expand at a double‑digit CAGR through 2030, making Swissport’s investments a strategic advantage.